Acute Sinusitis Market size is projected to be worth USD 3,319.41 million by 2027, registering a CAGR of 7.89% during the forecast period.
The Acute Sinusitis market is expected to reach USD 2.15 Billion by 2030 at 7.50% CAGR during the forecast period 2022-2030.
The growing number of people suffering from acute sinusitis, as well as the extensive range of treatment and diagnostic options available, are driving market expansion. However, the market's progress is hampered by a lack of awareness about acute sinusitis. Increased global R&D and healthcare spending, on the other hand, is expected to provide growth prospects for global market leaders.
Due to the COVID-19 restrictions and risk of getting infected by the virus, there was an extreme case of stress on the patients and the health workers. Also, a disruption in ear, nose, and throat (ENT) healthcare services, face-to-face (FTF) visits in both primary and secondary care were cancelled or limited. However, in the case of an emergency, the hospitals were open and accessible to the patients. The sale of OTC pain relievers increased as a result of self-care during the lockdown period.
Due to severe government limitations on transit of goods and services, the COVID-19 pandemic has a significant impact on acute sinusitis gadgets and drugs supply and demand in important locations. The enterprises are dealing with a variable demand flow that varies by area and market sector. As a result, they keep in touch with government officials on a regular basis to ensure that product supply is maintained over the border. The breakout of COVID-19 and the European government's subsequent steps to contain it have had an impact on the providers. The epidemic has also had a significant impact on Asia-Pacific countries such as China, Japan, and India. The demand-supply outlook has been significantly impacted by trade obstacles.
Acute sinusitis is mainly seen in adults as children have smaller and underdeveloped sinuses. Studies show that sinusitis occurs in 0.5% of all upper respiratory tract infections and has an incidence of 15–40 episodes per 1,000 patients every year. Furthermore, acute sinusitis is the second most commonly diagnosed infectious disease by general practitioners. As per an article published in February 2021 by WebMD LLC. (US), almost 35 million people in the US are affected by acute sinusitis, which is seen more in elderly (45 to 64 years) people. Over 15 million patients go for doctor visits every year in the US due to acute sinusitis. Furthermore, according to the World Allergy Organization, acute sinusitis has a yearly prevalence of 6–15% globally. Therefore, the increasing cases of acute sinusitis cases are expected to drive the growth of the global acute sinusitis market during the forecast period.
There is a lack of awareness regarding acute sinusitis among the general population, especially in developing nations, which may restrict the market growth. For instance, according to a study performed in Nigeria, Africa, in March 2020, out of a sample size of 2,912 patients, only 16.4% of them had awareness regarding nasal allergies and sinusitis. In another study done by the European Forum for Research and Education in Allergy and Airway Diseases (EUFORA) in October 2021, results found that there is a need for greater public awareness regarding sinusitis in Europe as well. Moreover, a large portion of the general population does not consult doctors for acute sinusitis and waits for the disease to heal itself. This is also due to a lack of awareness regarding the possible complications due to acute sinusitis.
Increasing R&D and healthcare expenditure supports innovation and the development of new technologies. There has been an increasing trend of healthcare R&D and expenditure globally that is expected to support growth for the acute sinusitis market in the future. For instance, OptiNose (US) had developed the first-ever FDA-approved nasal drug delivery system called fluticasone exhalation delivery system (EDS-FLU), which received a recommendation for treating nasal polyps in June 2021. Additionally, global healthcare expenditure is also seeing an increase, which is expected to keep increasing during the forecast period, creating lucrative growth and investment opportunities.
Value Chain Analysis
The global acute sinusitis market is growing at a significant rate due to the increasing number of players coming forward to provide products and services and the increasing number of patients suffering from acute sinusitis. The value chain analysis for the global acute sinusitis market comprises four major components that start with the research and product development (R&D), followed by the manufacturing of the products, distribution & sales, and ends with post-sales monitoring.
Acute Sinusitis Market Segmentation
Diagnosis & Treatment Insights
The diagnosis segment is categorized into nasal endoscopy, imaging test, clinical laboratory test, allergy testing. Diagnosis is expected to be a lucrative segment growing with a CAGR of 8.55% during the study period. The nasal endoscopy segment held largest share in the year 2020. This is due to the availability of advanced diagnostic services.
Based on the treatment, the segment is bifurcated into saline nasal spray, nasal corticosteroids, decongestants pain relievers, allergy shots, antibiotics. The saline nasal spray segment held majority of the shares in the year 2020. This is due to an increasing number of product launched by the key companies.
End User Insights
The hospitals & clinics segment held the largest market share in the global acute sinusitis market in 2020. This is due to increasing number of diagnostic and treatment approaches that are applied to address the inflammation incurred by patients at these healthcare centers.
Research centers and academic institutes engaged in finding better health outcomes for diagnosis and treatment regimens are anticipated to fuel the growth of this segment in the global market. Diagnostic companies are collaborating with research companies to conduct clinical trials. For instance, ENTvantage Dx (US) sponsored a study to evaluate the performance of a rapid in vitro diagnostic device for the qualitative detection of the three most common pathogens responsible for causing bacterial sinusitis in collaboration with Hillcrest Medical Research (US), ENT Allergy & Associates of South Florida (US), and Tandem Clinical Research (US), among others.
The others segment consists of diagnostic laboratories, radiography centers, and dedicated endoscopy centers.
The increasing prevalence of acute sinusitis and the presence of key players in the region are fueling growth for the Americas acute sinusitis market.
The Americas is segmented into North America and South America. The region held the largest market share in the year 2020. The increasing prevalence of acute sinusitis, growing awareness related to acute sinusitis, and the presence of key players in the region are some of the major attributing factors to the regional market growth. As per the Centers for Disease Control and Prevention (CDC), in 2018, there were about 28.9 million adults diagnosed with sinusitis in the US. Moreover, sinusitis accounted for about 11.6% of the adult population in the US. Thus, a high incidence rate of sinusitis in the region is one of the drivers for market growth.
Europe held the second largest market share in 2020. This is due to rising prevalence of sinusitis and the increasing geriatric population. Moreover, increasing initiatives by the government in the region for awareness of sinusitis is also influencing the market growth. Increasing healthcare expenditure and research funding coupled with the rising number of clinical trials has further boosted the market growth. For instance, the EU clinical trial register has 11 ongoing clinical trial studies focused on sinusitis treatment.
Improving healthcare infrastructure and increasing number of patients suffering from acute sinusitis, are anticipated to drive the market growth in the region.
The Asia-Pacific region is expected to witness the highest growth rate from 2022 to 2030. This is due to Improving healthcare infrastructure and the increasing number of patients suffering from acute sinusitis, which is stimulating the need for the adoption of acute sinusitis medications.
Moreover, the key players are expanding their presence in the region to diagnose and treat acute sinusitis. For instance, in December 2020, GlaxoSmithKline plc (UK) launched Otrivin Breathe Clean, a saline nasal wash for maintaining nasal hygiene in India. Likewise, in June 2020, Dr. Reddy’s Laboratories, Ltd. (India) acquired Wockhardt’s branded generics business in India and a few other international territories, including Nepal, Sri Lanka, Bhutan, and the Maldives. These factors are driving the growth of the acute sinusitis market in Asia-Pacific.
Middle East & Africa
The market for acute sinusitis is growing in the Middle East & Africa due to the booming geriatric population in the Middle Eastern countries and increasing healthcare spending in the region. Moreover, the increasing number of research companies and subsidiaries involved in R&D and increasing initiatives taken by the Middle East countries to develop their healthcare infrastructure is also contributing to the market growth.
Global acute sinusitis market is extremely competitive, with players competing, partnering, and investing heavily in R&D to gain a significant market share. The market is moderately fragmented with rising competition, product launches, increasing collaborative partnerships, and other strategic decisions to achieve operational efficiency.
The business model developed by manufacturers in the global acute sinusitis market includes manufacturing high-quality pharmaceutical products. Mergers and collaborations were also observed to expand the company's product portfolio and introduce new products. The growth of prominent industry players is dependent on various factors, such as market conditions, government support, and industry development. Key manufacturers in the acute sinusitis market are focusing on developing drugs with advanced technologies. It is also projected that rising global R&D initiatives and healthcare expenditure will boost the market's growth in the upcoming future.
List of companies with HQ
The study covers the existing short-term and long-term market effects. It helps decision-makers to draught short-term and long-term business plans by region. The report covers major regions in Americas, Europe, Asia Pacific, and the Middle East & Africa. The report analyzes market drivers, restraints, opportunities, challenges, Porter's five forces, value chain, and impact of COVID-19 on the market.
Market Segment Overview:
Diagnosis & Treatment Outlook
End User Outlook
|Market Size||2030: USD 2.15 Billion|
|Forecast Units||Value (USD Billion)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Diagnosis & Treatment type, End User, and Region|
|Geographies Covered||Americas, Europe, Asia Pacific, and Middle East & Africa|
|Key Vendors||Sanofi (France), Abbott (US), Bayer AG (Germany), Aurobindo Pharma (India), Bristol Myers Squibb (US), Merck KGaA (Germany), AstraZeneca (UK), Dr. Reddy’s Laboratories, Ltd (India), Novartis AG (Switzerland), GlaxoSmithKline plc (UK), Others|
|Key Market Opportunities||• Rising global R&D initiatives and healthcare expenditure|
|Key Market Drivers||• Increasing number of patients suffering from acute sinusitis • Availability of several treatment and diagnostic options|
Acute Sinusitis Market is projected to grow at a 7.50% CAGR between 2022-2030.
The Americas is expected to lead the Acute Sinusitis Market.
Rising prevalence of acute sinusitis and increasing number of diagnostic tests are adding market growth.
Unawareness about sinusitis may limit market growth.
End users of Acute Sinusitis Market include research centers and hospitals & clinics.